Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Dec 12, 2017 1:48pm
168 Views
Post# 27139869

RE:Look at this- Ken Dart

RE:Look at this- Ken DartGV, absolutely a great find and very interesting.

Dart Neurosciences closes it's San Diego research center.
  • started in 2008.
  • purpose was to discover ways of improving human memory. (wish it worked because I could use help)
  • $700 million plus invested. (I assume this includes many other investors????)
  • No evidence of any progress or any evidence of future progress, hence it has been shuttered.

Will this make Dart more interested in RVX and Zenith OR was this the reason for Dart drawing the line in the sand re the LOC with Citi and RVX on Dec 26th of this year. Is he pulling back on biotech investment?

$700,000,000 is far more than he has invested in RVX from what I recall and he lost it all. That must hurt even if he is worth $5.5 billion!!!

Thanks for post GV!
Cheers
Toinv


Bullboard Posts